Abiomed: Cardiologists Will Respond To Positive Trends In Unfinished Impella Trial
This article was originally published in The Gray Sheet
Executive Summary
Abiomed expects accelerated adoption of its Impella 2.5 circulatory support device based on partial data from a large study evaluating the system in high-risk, non-emergency angioplasty patients, despite having to stop the trial because it was deemed unlikely to meet its endpoint.